+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Overactive Bladder Treatment Market by Product Type, Therapeutic Class, Distribution Channel, Route of Administration, End User, Treatment Type, Age Group, Gender - Global Forecast to 2030- Product Image
Overactive Bladder Treatment Market by Product Type, Therapeutic Class, Distribution Channel, Route of Administration, End User, Treatment Type, Age Group, Gender - Global Forecast to 2030- Product Image
Sale

Overactive Bladder Treatment Market by Product Type, Therapeutic Class, Distribution Channel, Route of Administration, End User, Treatment Type, Age Group, Gender - Global Forecast to 2030

  • PDF Icon

    Report

  • 193 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968613
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The overactive bladder treatment market is undergoing significant transformation, propelled by advances in therapy, evolving patient demographics, and strategic shifts in healthcare delivery. Industry decision-makers are engaging with a landscape that demands agility and insight as new technologies, modalities, and regulatory factors shape market opportunities and risks.

Market Snapshot: Overactive Bladder Treatment Market

The Overactive Bladder Treatment Market grew from USD 4.71 billion in 2024 to USD 4.89 billion in 2025. It is expected to continue growing at a CAGR of 3.76%, reaching USD 5.88 billion by 2030. Growth is supported by expanding patient populations, a broader array of therapeutic options, and increasing adoption of advanced devices across global healthcare systems. Demand is further influenced by rising comorbidities and growing prioritization of value-based outcomes among healthcare stakeholders.

Scope & Segmentation: Meeting Varied Needs Across Stakeholders

  • Product Types: Anticholinergics (extended release, immediate release), beta-3 agonists (Mirabegron, Vibegron), botulinum toxin (Type A, Type B), neuromodulation devices (percutaneous tibial nerve stimulation, sacral neuromodulation)
  • Therapeutic Classes: Non-pharmacological (behavioral therapy, neuromodulation, pelvic floor muscle training), pharmacological (anticholinergics, beta-3 agonists, botulinum toxin)
  • Distribution Channels: Hospital, online, and retail pharmacies
  • Routes of Administration: Injectable, intravesical, oral, transcutaneous formats
  • End Users: Clinics, home care providers, hospitals
  • Treatment Types: Chemical (botulinum injection, drug therapy), surgical (implantable device, neuromodulation surgery)
  • Age Groups: Adult, geriatric, pediatric
  • Gender Segmentation: Female, male populations
  • Regional Coverage: Americas (including United States, Canada, Brazil, Mexico, and Argentina), Europe, Middle East & Africa (with key markets such as United Kingdom, Germany, France, Italy, Russia, and selected Middle Eastern and African nations), Asia-Pacific (featuring China, India, Japan, Australia, and Southeast Asia)
  • Leading Companies: Astellas Pharma Inc., Pfizer Inc., AbbVie Inc., Ferring B.V., Medtronic plc, Teva Pharmaceutical Industries Ltd., Axonics Modulation Technologies, Inc., Viatris Inc., Sandoz International GmbH, Eisai Co., Ltd.

Key Takeaways for Decision-Makers

  • Second-generation beta-3 agonists and combination therapies are challenging established treatment dominance and influencing clinical guidelines.
  • Non-pharmacological interventions, enabled by digital health integrations, are gaining acceptance and improving patient self-management outcomes.
  • Weighted emphasis on real-world effectiveness and patient quality of life is shaping payer and provider strategies in treatment selection and reimbursement.
  • Collaborative models—spanning pharma, device, and digital health firms—are redefining care pathways with more comprehensive post-treatment support.
  • A shift toward minimally invasive and device-assisted therapies is accelerating, with streamlined regulatory paths supporting adoption.

Tariff Impact: Navigating Policy-Driven Challenges

Recent United States tariffs have raised input costs across both drug manufacturing and device production in overactive bladder treatment. Pharmaceutical producers responded by diversifying supply chains, relocating production to tariff-exempt regions, or adopting vertical integration. Device manufacturers diversified production sites in Asia-Pacific and Europe, aiming to stabilize resources and shield supply. These changes elevated downstream costs for distributors and healthcare providers, influencing patient access, copayment structures, and timelines for advanced therapy adoption. Strategic partnerships for localized assembly and long-term agreements have emerged as mitigating strategies for supply chain resiliency.

Methodology & Data Sources

This analysis utilizes a multi-stage approach, blending secondary research from peer-reviewed sources, regulatory filings, and industry proceedings with primary interviews involving clinicians, payers, and patient advocates. Triangulation ensures findings reflect both supply and demand perspectives, with conclusions validated through cross-referencing and statistical review.

Why This Report Matters

  • Supports informed strategic planning and portfolio optimization, spotlighting innovation and competitive dynamics in overactive bladder therapies.
  • Equips decision-makers to address evolving technology, patient pathways, and local reimbursement considerations with data-driven insights.
  • Provides clarity on regional and segmental nuances, vital for effective market entry and investment prioritization.

Conclusion

Senior leaders gain actionable, unbiased analysis of the overactive bladder treatment market’s transformation and strategic landscape. Leveraging these insights will support stakeholder engagement, commercialization, and patient outcome optimization as the market continues to evolve.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Overactive Bladder Treatment Market, by Product Type
8.1. Introduction
8.2. Anticholinergics
8.2.1. Extended Release
8.2.2. Immediate Release
8.3. Beta-3 Agonists
8.3.1. Mirabegron
8.3.2. Vibegron
8.4. Botulinum Toxin
8.4.1. Type a
8.4.2. Type B
8.5. Neuromodulation Devices
8.5.1. Percutaneous Tibial Nerve Stimulation
8.5.2. Sacral Neuromodulation
9. Overactive Bladder Treatment Market, by Therapeutic Class
9.1. Introduction
9.2. Non Pharmacological
9.2.1. Behavioral Therapy
9.2.2. Neuromodulation
9.2.3. Pelvic Floor Muscle Training
9.3. Pharmacological
9.3.1. Anticholinergics
9.3.2. Beta-3 Agonists
9.3.3. Botulinum Toxin
10. Overactive Bladder Treatment Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Overactive Bladder Treatment Market, by Route of Administration
11.1. Introduction
11.2. Injectable
11.3. Intravesical
11.4. Oral
11.5. Transcutaneous
12. Overactive Bladder Treatment Market, by End User
12.1. Introduction
12.2. Clinic
12.3. Home Care
12.4. Hospital
13. Overactive Bladder Treatment Market, by Treatment Type
13.1. Introduction
13.2. Chemical
13.2.1. Botulinum Injection
13.2.2. Drug Therapy
13.3. Surgical
13.3.1. Implantable Device
13.3.2. Neuromodulation Surgery
14. Overactive Bladder Treatment Market, by Age Group
14.1. Introduction
14.2. Adult
14.3. Geriatric
14.4. Pediatric
15. Overactive Bladder Treatment Market, by Gender
15.1. Introduction
15.2. Female
15.3. Male
16. Americas Overactive Bladder Treatment Market
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. Argentina
17. Europe, Middle East & Africa Overactive Bladder Treatment Market
17.1. Introduction
17.2. United Kingdom
17.3. Germany
17.4. France
17.5. Russia
17.6. Italy
17.7. Spain
17.8. United Arab Emirates
17.9. Saudi Arabia
17.10. South Africa
17.11. Denmark
17.12. Netherlands
17.13. Qatar
17.14. Finland
17.15. Sweden
17.16. Nigeria
17.17. Egypt
17.18. Turkey
17.19. Israel
17.20. Norway
17.21. Poland
17.22. Switzerland
18. Asia-Pacific Overactive Bladder Treatment Market
18.1. Introduction
18.2. China
18.3. India
18.4. Japan
18.5. Australia
18.6. South Korea
18.7. Indonesia
18.8. Thailand
18.9. Philippines
18.10. Malaysia
18.11. Singapore
18.12. Vietnam
18.13. Taiwan
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Astellas Pharma Inc.
19.3.2. Pfizer Inc.
19.3.3. AbbVie Inc.
19.3.4. Ferring B.V.
19.3.5. Medtronic plc
19.3.6. Teva Pharmaceutical Industries Ltd.
19.3.7. Axonics Modulation Technologies, Inc.
19.3.8. Viatris Inc.
19.3.9. Sandoz International GmbH
19.3.10. Eisai Co., Ltd.
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. OVERACTIVE BLADDER TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. OVERACTIVE BLADDER TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. OVERACTIVE BLADDER TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 20. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2024 VS 2030 (%)
FIGURE 22. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. OVERACTIVE BLADDER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. OVERACTIVE BLADDER TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY MIRABEGRON, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY VIBEGRON, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY TYPE A, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY TYPE B, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PERCUTANEOUS TIBIAL NERVE STIMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SACRAL NEUROMODULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PELVIC FLOOR MUSCLE TRAINING, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY INTRAVESICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY TRANSCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY CHEMICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY CHEMICAL, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SURGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY IMPLANTABLE DEVICE, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY CHEMICAL, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY CHEMICAL, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 97. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 98. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 99. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2018-2030 (USD MILLION)
TABLE 100. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2030 (USD MILLION)
TABLE 101. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2018-2030 (USD MILLION)
TABLE 102. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 103. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 104. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 105. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 109. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY CHEMICAL, 2018-2030 (USD MILLION)
TABLE 110. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 111. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 112. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 113. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 114. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 115. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2018-2030 (USD MILLION)
TABLE 116. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2030 (USD MILLION)
TABLE 117. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2018-2030 (USD MILLION)
TABLE 118. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 119. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 120. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 121. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 125. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY CHEMICAL, 2018-2030 (USD MILLION)
TABLE 126. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 127. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 128. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY CHEMICAL, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY CHEMICAL, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2018-2030 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2018-2030 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY CHEMICAL, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 178. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 180. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2018-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2030 (USD MILLION)
TABLE 182. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY CHEMICAL, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 194. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 195. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 196. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2018-2030 (USD MILLION)
TABLE 197. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2030 (USD MILLION)
TABLE 198. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2018-2030 (USD MILLION)
TABLE 199. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 200. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 201. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 202. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 206. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY CHEMICAL, 2018-2030 (USD MILLION)
TABLE 207. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 208. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 209. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 210. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 211. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 212. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2018-2030 (USD MILLION)
TABLE 213. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2030 (USD MILLION)
TABLE 214. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2018-2030 (USD MILLION)
TABLE 215. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 216. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 217. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 218. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 222. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY CHEMICAL, 2018-2030 (USD MILLION)
TABLE 223. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 224. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 225. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 226. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 227. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 238. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY CHEMICAL, 2018-2030 (USD MILLION)
TABLE 239. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 240. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 241. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 242. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 243. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 244. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2018-2030 (USD MILLION)
TABLE 245. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2030 (USD MILLION)
TABLE 246. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2018-2030 (USD MILLION)
TABLE 247. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 248. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 249. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 250. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 254. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY CHEMICAL, 2018-2030 (USD MILLION)
TABLE 255. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 256. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 257. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 258. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 259. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 260. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2018-2030 (USD MILLION)
TABLE 261. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2030 (USD MILLION)
TABLE 262. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2018-2030 (USD MILLION)
TABLE 263. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 264. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 265. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 266. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 270. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY CHEMICAL, 2018-2030 (USD MILLION)
TABLE 271. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 272. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 273. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2030 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2018-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY CHEMICAL, 2018-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 290. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 291. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2030 (USD MILLION)
TABLE 292. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2018-2030 (USD MILLION)
TABLE 293. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2018-2030 (USD MILLION)
TABLE 294. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2018-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 296. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 298. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 300. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 302. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY CHEMICAL, 2018-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 304. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 306. SOUTH AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE,

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Overactive Bladder Treatment market report include:
  • Astellas Pharma Inc.
  • Pfizer Inc.
  • AbbVie Inc.
  • Ferring B.V.
  • Medtronic plc
  • Teva Pharmaceutical Industries Ltd.
  • Axonics Modulation Technologies, Inc.
  • Viatris Inc.
  • Sandoz International GmbH
  • Eisai Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages193
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 4.89 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.88 Billion
Compound Annual Growth Rate3.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report - Product Image

Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
Overactive Bladder Epidemiology Forecast 2025-2034 - Product Image

Overactive Bladder Epidemiology Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From
Overactive Bladder Treatment Market Report 2025 - Product Image

Overactive Bladder Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Overactive Bladder Therapeutics Market 2025-2029 - Product Image

Overactive Bladder Therapeutics Market 2025-2029

  • Report
  • 221 Pages
  • Global
From
Overactive Bladder Treatment Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Overactive Bladder Treatment Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 96 Pages
  • Global
From

About the Overactive Bladder Drug Market

The Overactive Bladder Drug market is a subset of the Urological Disorders Drugs market. It is composed of drugs used to treat overactive bladder, a condition characterized by frequent urination, urgency, and incontinence. These drugs work by relaxing the bladder muscles, reducing the urge to urinate, and improving bladder control. Commonly used drugs include anticholinergics, beta-3 agonists, and muscarinic receptor antagonists. These drugs are available in both oral and topical formulations. The Overactive Bladder Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Astellas Pharma, Allergan, Merck, Sanofi, and GlaxoSmithKline. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.